FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.